In a recent transaction, Allison Hoffman, the General Counsel & Secretary of Phreesia, Inc. (NYSE:PHR), sold 14,110 shares of company stock, resulting in a total sale value of approximately $367,240. This sale was executed at a weighted average price of $26.027 per share, with individual transactions occurring within a price range of $25.515 to $26.36 per share.
The sale took place on August 26, 2024, and was disclosed in a regulatory filing with the Securities and Exchange Commission (SEC). Following the sale, Hoffman holds a total of 121,003 shares in Phreesia, indicating a continued vested interest in the company's performance.
The transaction was part of a mandatory sell-to-cover policy that the company enforces to manage tax withholding obligations related to the settlement of restricted stock units. Hoffman's sale was not discretionary but was required to cover specific tax liabilities that arise from equity compensation.
Investors often monitor insider transactions as they can provide insights into the confidence levels of the company's executives and their outlook on the company's future performance. In the case of Phreesia, this recent sale by a high-ranking executive is part of a structured financial planning strategy rather than an elective trading decision.
Phreesia, Inc. specializes in healthcare software solutions and has made strides in streamlining patient intake processes for medical organizations. The company's stock is publicly traded on the New York Stock Exchange under the ticker symbol PHR.
In other recent news, Phreesia, a leader in patient intake and engagement solutions, has seen notable developments. The company reported a substantial 21% increase in revenue, reaching $101.2 million, and a positive adjusted EBITDA of $4.1 million. Despite these financial gains, Phreesia revised its revenue guidance downward by $8 million due to the early conclusion of a clearinghouse partnership.
In the realm of strategic appointments, Phreesia has brought on healthcare veteran Bob Glazer as a Strategic Advisor. Glazer's extensive experience, including a 27-year tenure as CEO of ENT and Allergy Associates, is expected to enhance Phreesia's services.
In terms of stockholder decisions, three Class II directors were elected to serve a three-year term, and stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending January 31, 2025.
On the analysts' front, DA Davidson reaffirmed a Buy rating on Phreesia, highlighting the company's growth potential. JPMorgan (NYSE:JPM) adjusted its price target on Phreesia shares to $27, maintaining an 'Overweight' rating, while RBC Capital held steady with a 'Sector Perform' rating and a price target of $23. These are the latest updates for Phreesia.
InvestingPro Insights
As investors digest the news of Allison Hoffman's recent stock sale, a closer look at Phreesia, Inc. (NYSE:PHR) through InvestingPro reveals several key financial metrics and expert analysis that may influence their perspective. With a market capitalization of $1.45 billion, Phreesia is navigating the competitive healthcare software market with notable revenue growth. The company's revenue in the last twelve months as of Q1 2025 stands at $373.67 million, marking a significant increase of 23.98%.
InvestingPro Tips highlight that analysts have recently revised their earnings estimates upwards for the upcoming period, reflecting a potential positive shift in the company's financial trajectory. However, it is important to note that analysts do not expect Phreesia to be profitable this year, as evidenced by the negative P/E ratio of -11.52. The company has been operating with a moderate level of debt and has not been profitable over the past twelve months. It is also trading at a high Price/Book multiple of 5.64, which suggests that the stock may be valued more for its growth potential than for its current assets.
Despite not paying dividends, Phreesia's stock has experienced a 1-week price total return of 1.89% and a 3-month return of 11.99%, as of late 2024. The company's fair value, as assessed by analysts, is $29 per share, while InvestingPro's fair value estimate is slightly lower at $27.93. For investors seeking additional insights, InvestingPro offers more tips on Phreesia and other companies to help guide investment decisions.
For those interested in a deeper analysis, InvestingPro has over five additional tips available, offering a more comprehensive understanding of Phreesia's financial health and future prospects. These insights can be accessed through the platform's dedicated page for Phreesia at https://www.investing.com/pro/PHR.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.